Abstract
Proton therapy (PT) is a high-precision form of radiotherapy. The interest in clinical application in oncology of PT is related to its ballistic selectivity capable to adequately cover the tumor target with high homogeneity, high conformality and sparing the surrounding organ at risk (OAR), mainly in the middle-low dose area, with a potential significant reduction of toxicity and development of radio-induced second tumors. PT has gained a renewed interest in very recent years after its first pioneering beginning in Berkeley in 1954 due to the advancement in treatment planning, delivery systems (gantry), radiobiological knowledge and clinical imaging. This fact has permitted the transit of PT from laboratory research structures to modern clinically-oriented treatment facilities. The results of PT in some specific sites such as ocular tumors and base of the skull tumors are well known approaching local control rates at five years of 100% and 90%, respectively. Indications are now evolving towar ds the treatment of other very common tumors such as lung, head and neck, liver: all of them show very attractive response rates. A particular interest is now growing for pediatric tumors considering the possibility of reducing not only the dose to OAR but also the integral dose. Integration with chemotherapy represents another challenge thanks to the possibility of increasing dose intensity of chemotherapy or total radiation dose and/or reducing the toxicity of the combined treatment.
Keywords: Proton therapy, radiotherapy, chemotherapy, cancer
Current Drug Therapy
Title: A Review of the Current Role of Proton Therapy in Modern Oncology
Volume: 2 Issue: 2
Author(s): Maurizio Amichetti, Augusto Lombardi, Carlo Algranati, Marco Schwarz, Marco Cianchetti and Lamberto Widesott
Affiliation:
Keywords: Proton therapy, radiotherapy, chemotherapy, cancer
Abstract: Proton therapy (PT) is a high-precision form of radiotherapy. The interest in clinical application in oncology of PT is related to its ballistic selectivity capable to adequately cover the tumor target with high homogeneity, high conformality and sparing the surrounding organ at risk (OAR), mainly in the middle-low dose area, with a potential significant reduction of toxicity and development of radio-induced second tumors. PT has gained a renewed interest in very recent years after its first pioneering beginning in Berkeley in 1954 due to the advancement in treatment planning, delivery systems (gantry), radiobiological knowledge and clinical imaging. This fact has permitted the transit of PT from laboratory research structures to modern clinically-oriented treatment facilities. The results of PT in some specific sites such as ocular tumors and base of the skull tumors are well known approaching local control rates at five years of 100% and 90%, respectively. Indications are now evolving towar ds the treatment of other very common tumors such as lung, head and neck, liver: all of them show very attractive response rates. A particular interest is now growing for pediatric tumors considering the possibility of reducing not only the dose to OAR but also the integral dose. Integration with chemotherapy represents another challenge thanks to the possibility of increasing dose intensity of chemotherapy or total radiation dose and/or reducing the toxicity of the combined treatment.
Export Options
About this article
Cite this article as:
Amichetti Maurizio, Lombardi Augusto, Algranati Carlo, Schwarz Marco, Cianchetti Marco and Widesott Lamberto, A Review of the Current Role of Proton Therapy in Modern Oncology, Current Drug Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488507780619068
DOI https://dx.doi.org/10.2174/157488507780619068 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews Neuro-toxic and Reproductive Effects of BPA
Current Neuropharmacology Molecular Basis of Young Ischemic Stroke
Current Medicinal Chemistry Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology The Prognostic and Predictive Value of microRNAs in Patients with H. pylori-positive Gastric Cancer
Current Pharmaceutical Design Subject Index To Volume 3
Current Genomics Microarray-Based Identification of New Targets for Specific Therapies in Pediatric Leukemia
Current Drug Targets In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Familial Hypercholesterolemia: Update and Review
Endocrine, Metabolic & Immune Disorders - Drug Targets At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Immunotherapy of HCC
Reviews on Recent Clinical Trials Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy